The name Cosentyx was derived as part of a name bank creation exercise for the Novartis pipeline of future products.
Cosentyx (secukinumab) was the first FDA-approved biologic treatment of its kind. Biologic drugs are protein-based medications that are made from living sources and taken by injection or infusion.
It is used to treat moderate to severe plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis in adults. Working as an immunosuppressant that reduces the effects of a chemical substance in the body that can cause inflammation.
Cosentyx is an arbitrary coinage, the word suggests comfort and strength, it sounds fast-acting and conveys ideas of regaining balance, control and improved efficacy.